Sung, H., Ferlay, J., Siegel, R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:3 (2021), 209–249.
Arbyn, M., Weiderpass, E., Bruni, L., et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:2 (2020), e191–e203.
Cohen, P.A., Jhingran, A., Oaknin, A., Denny, L., Cervical cancer. Lancet 393:10167 (2019), 169–182.
Hebner, C.M., Laimins, L.A., Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16:2 (2006), 83–97.
Barillari, G., Monini, P., Sgadari, C., Ensoli, B., The impact of Human Papilloma Viruses, matrix metallo-proteinases and HIV protease inhibitors on the onset and progression of uterine cervix epithelial tumors: a review of preclinical and clinical studies. Int J Mol Sci, 19(5), 2018, 1418.
Adegoke, O., Kulasingam, S., Virnig, B., Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 21:10 (2012), 1031–1037.
Zappa, M., Visioli, C.B., Ciatto, S., Iossa, A., Paci, E., Sasieni, P., Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 90:9 (2004), 1784–1786.
Cibula, D., Pötter, R., Planchamp, F., et al. The European Society of Gynaecological Oncology/European Society for radiotherapy and oncology/European society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer 28:4 (2018), 641–655.
Gennigens, C., De Cuypere, M., Hermesse, J., Kridelka, F., Jerusalem, G., Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther 21:6 (2021), 657–671.
Sardain, H., Lavoue, V., Redpath, M., Bertheuil, N., Foucher, F., Levêque, J., Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review. Eur J Surg Oncol 41:8 (2015), 975–985.
Thigpen, T., Shingleton, H., Homesley, H., Lagasse, L., Blessing, J., Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48:4 (1981), 899–903.
Bonomi, P., Blessing, J.A., Stehman, F.B., DiSaia, P.J., Walton, L., Major, F.J., Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:8 (1985), 1079–1085.
Tsuda, N., Watari, H., Ushijima, K., Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res 28:2 (2016), 241–253.
Long, H.J. 3rd, Bundy, B.N., Grendys, E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:21 (2005), 4626–4633.
Monk, B.J., Sill, M.W., McMeekin, D.S., et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:28 (2009), 4649–4655.
Moore, D.H., Blessing, J.A., McQuellon, R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:15 (2004), 3113–3119.
Zanetta, G., Fei, F., Parma, G., et al. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 10:10 (1999), 1171–1174.
Bloss, J.D., Blessing, J.A., Behrens, B.C., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:7 (2002), 1832–1837.
Kitagawa, R., Katsumata, N., Shibata, T., et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase III trial JCOG0505. J Clin Oncol 33:19 (2015), 2129–2135.
Eskander, R.N., Tewari, K.S., Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 11:6 (2015), 909–922.
Gaffney, D.K., Haslam, D., Tsodikov, A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 56:4 (2003), 922–928.
Ceci, C., Atzori, M.G., Lacal, P.M., Graziani, G., Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models. Int J Mol Sci, 21(4), 2020, E1388.
Minion, L.E., Tewari, K.S., Cervical cancer-state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 148:3 (2018), 609–621.
Tewari, K.S., Sill, M.W., Long, H.J. 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:8 (2014), 734–743.
Tewari, K.S., Sill, M.W., Penson, R.T., et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:10103 (2017), 1654–1663.
Monk, B.J., Mas Lopez, L., Zarba, J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:22 (2010), 3562–3569.
Symonds, R.P., Gourley, C., Davidson, S., et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 16:15 (2015), 1515–1524.
Mackay, H.J., Tinker, A., Winquist, E., et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 116:2 (2010), 163–167.
Vergote, I., Van Nieuwenhuysen, E., Casado, A., et al. 199 randomised phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Int J Gynecol Cancer, 31(suppl 3), 2021, A12.
Tian, W.J., Huang, M.L., Qin, Q.F., Chen, Q., Fang, K., Wang, P.L., Prognostic impact of epidermal growth factor receptor overexpression in patients with cervical cancer: a meta-analysis. PLoS One, 11(7), 2016, e0158787.
Noordhuis, M.G., Eijsink, J.J.H., Ten Hoor, K.A., et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 15:23 (2009), 7389–7397.
Kersemaekers, A.M., Fleuren, G.J., Kenter, G.G., et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 5:3 (1999), 577–586.
Itkin, B., Garcia, A., Straminsky, S., et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS One, 16(9), 2021, e0257976.
Santin, A.D., Sill, M.W., McMeekin, D.S., et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 122:3 (2011), 495–500.
Goncalves, A., Fabbro, M., Lhommé, C., et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 108:1 (2008), 42–46.
Schilder, R.J., Sill, M.W., Lee, Y.C., Mannel, R., A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 19:5 (2009), 929–933.
Oaknin, A., Friedman, C.F., Roman, L.D., et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial. Gynecol Oncol 159:1 (2020), 150–156.
Wakabayashi, R., Nakahama, Y., Nguyen, V., Espinoza, J.L., The host-microbe interplay in human papillomavirus-induced carcinogenesis. Microorganisms, 7(7), 2019, E199.
Mezache, L., Paniccia, B., Nyinawabera, A., Nuovo, G.J., Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 28:12 (2015), 1594–1602.
Heeren, A.M., Punt, S., Bleeker, M.C., et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 29:7 (2016), 753–763.
Cao, Y., Zhou, X., Huang, X., et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One, 8(1), 2013, e53834.
Kosmaczewska, A., Bocko, D., Ciszak, L., et al. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res 18:2 (2012), 479–489.
Piersma, S.J., Jordanova, E.S., van Poelgeest, M.I.E., et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67:1 (2007), 354–361.
Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., Wang, Y., A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 8:1 (2011), 59–66.
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
Chalmers, Z.R., Connelly, C.F., Fabrizio, D., et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med, 9(1), 2017, 34.
Cohen, A.C., Roane, B.M., Leath, C.A., Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy. Drugs 80:3 (2020), 217–227.
Kagabu, M., Nagasawa, T., Sato, C., et al. Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. Int J Mol Sci, 21(7), 2020, E2335.
Omenai, S.A., Ajani, M.A., Okolo, C.A., Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients. PLoS One, 17(2), 2022, e0263615.
Frenel, J.S., Le Tourneau, C., O'Neil, B., et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-Positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol 35:36 (2017), 4035–4041.
Chung, H.C., Ros, W., Delord, J.P., et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37:17 (2019), 1470–1478.
Chung, H., Delord, J.P., Perets, R., et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase II KEYNOTE-158 study. Gynecol Oncol, 162(suppl 1), 2021, S27.
Naumann, R.W., Hollebecque, A., Meyer, T., et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol 37:31 (2019), 2825–2834.
Santin, A.D., Deng, W., Frumovitz, M., et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 157:1 (2020), 161–166.
O'Malley, D.M., Oaknin, A., Monk, B.J., et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol 163:2 (2021), 274–280.
Tewari, K.S., Monk, B.J., Vergote, I., et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med 386:6 (2022), 544–555.
Lheureux, S., Butler, M.O., Clarke, B., et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol, 4(7), 2018, e173776.
Colombo, N., Dubot, C., Lorusso, D., et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 385:20 (2021), 1856–1867.
Naumann, R.W., Oaknin, A., Meyer, T., et al. LBA62-Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358. Ann Oncol 30:suppl 5 (2019), v898–v899.
O'Malley, D.M., Randall, L.M., Jackson, C.G., et al. RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer. Future Oncol 17:26 (2021), 3433–3443.
O'Malley, D.M., Neffa, M., Monk, B.J., et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol 40 (2022), 762–771.
Akeso, Inc | New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA. Published September 24, 2021. Available at https://www.akesobio.com/en/media/akeso-news/210924/. Accessed November 6, 2021.
Akesobio, Inc. 2020 Annual Results Presentation. Published online March 2021. Available at https://www.akesobio.com/media/1404/akesoplus2020plusarpluspresentation_ve-website.pdf. Accessed November 5, 2021.
Lee, W.S., Yang, H., Chon, H.J., Kim, C., Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52:9 (2020), 1475–1485.
Friedman, C.F., Snyder Charen, A., Zhou, Q., et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer, 8(2), 2020, e001126.
Lan, C., Shen, J., Wang, Y., et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol 38:34 (2020), 4095–4106.
Strauss, J., Gatti-Mays, M.E., Cho, B.C., et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer, 8(2), 2020, e001395.
Strauss, J., Braiteh, F.S., Calvo, E., et al. Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies. J Clin Oncol, 39(suppl 15), 2021, 5509 5509.
Harjunpää, H., Guillerey, C., TIGIT as an emerging immune checkpoint. Clin Exp Immunol 200:2 (2020), 108–119.
Shi, A.P., Tang, X.Y., Xiong, Y.L., et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol, 12, 2021, 785091.
Vici, P., Mariani, L., Pizzuti, L., et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res, 33(1), 2014, 29.
Melief, C.J.M., Welters, M.J.P., Vergote, I., et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med, 12(535), 2020, eaaz8235.
Youn, J.W., Hur, S.Y., Woo, J.W., et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol 21:12 (2020), 1653–1660.
Hillemanns, P., Baurain, J.F., Blecharz, P., et al. 881TiP A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer. Ann Oncol 31:suppl 4 (2020), S645–S646.
Ghamande, S.A., Platt, D., Wheatley, D., Rungruang, B.J., Janik, J.E., Khleif, S., Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer. J Clin Oncol, 34(suppl 15), 2016, e14580.
Huh, W.K., Dizon, D.S., Powell, M.A., et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage I of the phase II GOG/NRG0265 study. J Clin Oncol, 34(suppl 15), 2016, 5516.
Basu, P., Mehta, A., Jain, M., et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-Listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer 28:4 (2018), 764–772.
Slomovitz, B., Bradley, W.H., Ghamande, S., et al. Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer. Gynecol Oncol 159:suppl 1 (2020), 4–5.
Mayor, P., Starbuck, K., Zsiros, E., Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150:2 (2018), 361–369.
Stevanović, S., Draper, L.M., Langhan, M.M., et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33:14 (2015), 1543–1550.
Jazaeri, A.A., Zsiros, E., Amaria, R.N., et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol, 37(suppl 15), 2019, 2538.
O'Malley, D., Lee, S., Psyrri, A., et al. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers. J Immunother Cancer, 9(suppl 2), 2021.
Skorka, K., Ostapinska, K., Malesa, A., Giannopoulos, K., The application of CAR-T cells in haematological malignancies. Arch Immunol Ther Exp (Warsz), 68(6), 2020, 34.
Larson, R.C., Maus, M.V., Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 21:3 (2021), 145–161.
Chu, A.J., Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam, 2011, 2011, 367284.
de Bono, J.S., Concin, N., Hong, D.S., et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol 20:3 (2019), 383–393.
Hong, D.S., Concin, N., Vergote, I., et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 26:6 (2020), 1220–1228.
Coleman, R.L., Lorusso, D., Gennigens, C., et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:5 (2021), 609–619.
Monk, B., Van Gorp, T., Lorusso, D., et al. Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results. Int J Gynecol Cancer 31:suppl 4 (2021), A7–A8.
Lorusso, D., Vergote, I., O'Cearbhaill, R.E., et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): interim results of ENGOT Cx8/GOG 3024/innovaTV 205. J Clin Oncol, 40, 2022, 5507.
Vergote, I., Randall, L.M., Kalbacher, E., et al. EPV255/#120 Tisotumab vedotin vs investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress). Int J Gynecol Cancer 31:suppl 4 (2021), A129–A130.
Morotti, M., Albukhari, A., Alsaadi, A., et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer 124:11 (2021), 1759–1776.
Jentschke, M., Kampers, J., Becker, J., Sibbertsen, P., Hillemanns, P., Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine 38:41 (2020), 6402–6409.
Casajuana-Pérez, A., Ramírez-Mena, M., Ruipérez-Pacheco, E., et al. Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL/CIN 2-3: The VENUS study. Vaccines (Basel), 10(2), 2022, 288.
